Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin

Journal of Molecular and Cellular Cardiology

Volumn 45, Issue 6, 2008, Pages 715-723

  Liu, Fang ^a   Levin, Mark D ^a,b   Petrenko, Nataliya B ^a   Lu, Min Min ^a   Wang, Tao ^a   Yuan, Li Jun ^a   Stout, Andrea L ^c   Epstein, Jonathan A ^a,b,c   Patel, Vickas V ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Atrial arrhythmias; Connexin40; Fibrosis; Heart failure; Histone deacetylases

Indexed keywords

ANGIOTENSIN II; CONNEXIN 40; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HOMEODOMAIN PROTEIN; TRICHOSTATIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENZYME INHIBITION; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEMODYNAMIC MONITORING; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING; WILD TYPE;

ANGIOTENSIN II; ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOMEGALY; CONNEXINS; ENZYME INHIBITORS; FIBROSIS; HISTONE DEACETYLASES; HOMEODOMAIN PROTEINS; HYDROXAMIC ACIDS; MICE; MICE, TRANSGENIC; TIME FACTORS;

MUS;

EID: 55649123444     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2008.08.015     Document Type: Article

References (24)

1. Tsang T.S., Gersh B.J., Appleton C.P., Tajik A.J., Barnes M.E., Bailey K.R., et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J. Am. Coll. Cardiol. 40 (2002) 1636-1644
2. Okin P.M., Wachtell K., Devereux R.B., Harris K.E., Jern S., Kjeldsen S.E., et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 296 (2006) 1242-1248
3. Rotter M., Jais P., Garrigue S., Sanders P., Hocini M., Hsu L.F., et al. Clinical predictors of noninducibility of sustained atrial fibrillation after pulmonary vein isolation. J. Cardiovasc. Electrophysiol. 16 (2005) 1298-1303
4. Li D., Fareh S., Leung T.K., and Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100 (1999) 87-95
5. Li D., Shinagawa K., Pang L., Leung T.K., Cardin S., Wang Z., et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104 (2001) 2608-2614
6. Cardin S., Li D., Thorin-Trescases N., Leung T.K., Thorin E., and Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc. Res. 60 (2003) 315-325
7. Kook H., Lepore J.J., Gitler A.D., Lu M.M., Wing-Man Yung W., Mackay J., et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein. Hop. J. Clin. Invest. 112 (2003) 863-871
8. Hanna N., Cardin S., Leung T.K., and Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc. Res. 63 (2004) 236-244
9. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M.A., and Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96 (1997) 1180-1184
10. Schoonderwoerd B.A., Van Gelder I.C., Van Veldhuisen D.J., Van den Berg M.P., and Crijns H.J.G.M. Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation. Prog. Cardiovasc. Dis. 48 (2005) 153-168
11. Milliez P., DeAngelis N., Rucker-Martin C., Leenhardt A., Vicaut E., Robidel E., et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur. Heart J. 26 (2005) 2193-2199
12. Kee H.J., Sohn I.S., Nam K.I., Park J.E., Qian Y.R., Yin Z., et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113 (2006) 51-59
13. Kong Y., Tannous P., Lu G., Berenji K., Rothermel B.A., Olson E.N., et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113 (2006) 2579-2588
14. Rombouts K., Niki T., Greenwel P., Vandermonde A., Wielant A., Hellemans K., et al. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-β1-induced fibrogenesis in skin fibroblasts. Exp. Cell Res. 278 (2002) 184-197
15. Arndt M., Lendeckel U., Rocken C., Nepple K., Wolke C., Spiess A., et al. Altered expression of ADAMs (A Disintegrin And Metalloproteinase) in fibrillating human atria. Circulation 105 (2002) 720-725
16. Polontchouk L., Haefliger J.A., Ebelt B., Schaefer T., Stuhlmann D., Mehlhorn U., et al. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J. Am. Coll. Cardiol. 38 (2001) 883-891
17. Vermes E., Tardif J.C., Bourassa M.G., Racine N., Levesque S., White M., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 107 (2003) 2926-2931
18. Lee K.W., Everett T.H.I.V., Rahmutula D., Guerra J.M., Wilson E., Ding C., et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 114 (2006) 1703-1712
19. Burstein B., Libby E., Calderone A., and Nattel S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 117 (2008) 1630-1641
20. Verheule S., Sato T., Everett IV T., Engle S.K., Otten D., Rubart-von der Lohe M., et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-β1. Circ. Res. 94 (2004) 1458-1465
21. Nattel S., Maguy A., Le Bouter S., and Yeh Y.H. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction and atrial fibrillation. Physiol. Rev. 87 (2007) 425-456
22. Hagendorff A., Schumacher B., Kirchhoff S., Lüderitz B., and Willecke K. Conduction disturbances and increased atrial vulnerability in connexin40-deficient mice analyzed by transesophageal stimulation. Circulation 99 (1999) 1508-1515
23. Kanagaratnam P., Cherian A., Stanbridge R.D.L., Glenville B., Severs N.J., and Peters N.S. Relationship between connexins and atrial activation during human atrial fibrillation. J. Cardiovasc. Electrophysiol. 15 (2004) 206-216
24. Beauchamp P., Yamada K.A., Baertschi A.J., Green K., Kanter E.M., Saffitz J.E., et al. Relative contributions of connexins 40 and 43 to atrial impulse propagation in synthetic strands of neonatal and fetal murine cardiomyocytes. Circ. Res. 99 (2006) 1216-1224